The data of 9 patients with stage Ⅲ/Ⅳ extranodal nasal-type natural killer/T cell lymphoma from August 2019 to August 2020 in People's Hospital of Zhengzhou University was retrospectively analyzed. All the patients were treated with the programmed cell death-1 (PD-1) inhibitor combined with P-GemoX-DEX (gemcitabine+oxaliplatin+dexamethasone+peraspartase) regimen as the first-line treatment. After 4 cycles of treatment, positron emission tomography/computed tomography (PET/CT) was used to evaluate the curative effect, and adverse reactions were also observed. The median follow-up time was 7 months. The overall response rate, complete and partial remission rate was 9/9, 6/9 and 3/9, respectively. The main adverse event was hematological toxicity, with 6 cases of grade Ⅰ/Ⅱ neutropenia, and no immune-related adverse events were reported.
回顾性分析郑州大学人民医院2019年8月至2020年8月初治Ⅲ/Ⅳ期结外NK/T细胞淋巴瘤（ENKTL）患者资料。9例患者采用了程序性死亡受体1（PD-1）抑制剂联合P-Gemox-Dex（吉西他滨+奥沙利铂+地塞米松+培门冬酶）方案作为一线治疗方案，4周期治疗结束后，采用正电子发射计算机断层扫描（PET/CT）评估疗效，并观察不良反应。9例患者中位随访时间为7个月，总有效率为9/9，完全缓解6例，部分缓解3例。主要不良事件为血液学毒性，6例患者出现Ⅰ~Ⅱ度中性粒细胞减少，未见免疫相关的不良事件。.